News

Doximity: Demand For AI-Driven Platforms In The Medical Sector Drives Longer-Term Buy

Doximity is a clear winner in key fundamentals like 5-year revenue CAGR, ROCE, and profit margin. Find out why DOCS stock is a buy.

SeekingAlpha·06:27DOCS▲+0.5%

Why Is Doximity (DOCS) Stock Rocketing Higher Today

Shares of medical professional network Doximity (NYSE:DOCS) jumped 7.3% in the afternoon session after the company announced a partnership with Wolters Kluwer Health to integrate UpToDate clinical content into its Doximity Ask platform.

Yahoo·17:01DOCS▲+0.5%

OpenEvidence, Doximity settle thorny AI legal battle

The health AI companies are putting to bed a legal dispute involving dueling lawsuits, claims of corporate espionage and allegations of harassment.

Yahoo·11:30DOCS▲+0.5%

Doximity and Wolters Kluwer Sign Partnership to Bring UpToDate to Doximity Ask

SAN FRANCISCO & WALTHAM, Mass., October 20, 2026--Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, and Wolters Kluwer Health, today announced that UpToDate’s trusted, evidence-based, clinical content will be accessible directly within Doximity’s fast-growing AI clinical decision support tool, Ask.

Yahoo·09:30DOCS▲+0.5%

Why Doximity (DOCS) Dipped More Than Broader Market Today

Doximity (DOCS) closed the most recent trading day at $30.71, moving 2.51% from the previous trading session.

Yahoo·17:15DOCS▲+0.5%

Doximity to Release Fiscal 2027 Second Quarter Results on November 5, 2026

SAN FRANCISCO, October 15, 2026--Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal second quarter ended September 30, 2026 after market close on November 5, 2026. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial results.

Yahoo·16:05DOCS▲+0.5%

Doximity Deepens U.S. News Alliance to Improve Patient Access to Care

DOCS extends its 13-year partnership with U.S. News, strengthening its role in physician searches, appointment booking and hospital rankings.

Yahoo·10:45DOCS▲+0.5%

Doximity Reports Q1 2027 Results: Full Earnings Call Transcript

Doximity (NYSE:DOCS) released first-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and

Benzinga·00:49DOCS▲+0.5%

Doximity and U.S. News & World Report Extend Partnership to Connect Patients with Hospitals and Doctors

Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced it has extended its 13-year partnership with U.S. News & World Report, the nation's most trusted source of independent healthcare information, rankings and guidance to help patients identify the best care for their needs.

Yahoo·00:01DOCS▲+0.5%

Reflecting On Vertical Software Stocks’ Q2 Earnings: Doximity (NYSE:DOCS)

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Doximity (NYSE:DOCS) and its peers.

Yahoo·16:43DOCS▲+0.5%

Is Doximity (DOCS) Below Fair Value Following The AI Spending Surge?

Doximity (DOCS) caught fresh attention after its shares moved higher on a report showing a jump in infrastructure service spending tied to artificial intelligence, prompting investors to reassess the stock’s AI exposure. Short term momentum around Doximity has turned sharply positive, with a 1-day share price return of 6.10% and a 30-day share price return of 20.31% building on a 90-day gain of 34.96%. However, the stock is still down 32.13% on a year-to-date share price basis and long term...

Yahoo·02:14DOCS0.5%

Palantir Technologies, Doximity, Snowflake, and Teradata Shares Skyrocket, What You Need To Know

A number of stocks jumped in the afternoon session after a comprehensive industry report revealed that infrastructure service spending surged by more than double in the third quarter thanks to accelerating artificial intelligence adoption.

Yahoo·18:16DOCS▲+0.5%

Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing

The latest trading day saw Doximity (DOCS) settling at $28.58, representing a +2.33% change from its previous close.

Yahoo·17:15DOCS▲+0.5%

UiPath, monday.com, Amplitude, Doximity, and Sprinklr Shares Skyrocket, What You Need To Know

A number of stocks jumped in the afternoon session after the Bureau of Economic Analysis reported a 0.9% increase in personal consumption expenditures for August, signaling resilient consumer demand alongside steady economic expansion.

Yahoo·19:01DOCS▲+0.5%

Doximity (DOCS) Gains As Market Dips: What You Should Know

In the latest trading session, Doximity (DOCS) closed at $26.52, marking a +1.22% move from the previous day.

Yahoo·17:15DOCS▲+0.5%

Evercore ISI Group Maintains In-Line on Doximity, Lowers Price Target to $35

Evercore ISI Group analyst Elizabeth Anderson maintains Doximity (NYSE:DOCS) with a In-Line and lowers the price target from $40 to $35.

Benzinga·07:17DOCS▲+0.5%

3 Profitable Stocks with Warning Signs

Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.

Yahoo·05:52

What Doximity (DOCS)'s Bedside Bench AI Benchmark Launch Means For Shareholders

Doximity recently launched Bedside Bench, an open-source benchmark designed to evaluate clinical-grade AI using realistic bedside scenarios, and independent testing by Fireworks ranked its Doximity Ask system ahead of several frontier models. This move highlights how domain-specific, healthcare-focused AI can outperform general-purpose systems on clinically relevant tasks, potentially strengthening Doximity’s positioning as a trusted tool for physicians. We’ll now examine how Doximity’s...

Yahoo·22:12DOCS▲+0.5%

Doximity Named Leading Clinical AI Benchmark in Fireworks’ Cross-Industry Index

SAN FRANCISCO, September 22, 2026--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced that it has been named a founding partner in the launch of a new Specialized Intelligence Index of leading AI benchmarks compiled by Fireworks, the AI training and inference platform.

Yahoo·18:35

Doximity (DOCS) Surpasses Market Returns: Some Facts Worth Knowing

In the closing of the recent trading day, Doximity (DOCS) stood at $26.84, denoting a +2.8% move from the preceding trading day.

Yahoo·18:15DOCS▲+0.5%

Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note

Doximity (DOCS) closed at $25.81 in the latest trading session, marking a -2.2% move from the prior day.

Yahoo·18:15DOCS▲+0.5%

Neuraxis Gains Nearly 137% in a Year: What's Driving the Stock?

NRXS is benefiting from stronger IB-Stim volumes, broader reimbursement and VA access, but incomplete payer coverage and cash needs remain challenges.

Yahoo·11:11

Doximity’s ex-chief revenue officer to pay nearly $500K to SEC: Trial Balance

Paul Jorgensen has been ordered to pay the sum in the wake of allegations of insider trading.

Yahoo·06:03DOCS▲+0.5%

Veteran Health Tech Leader Jim Longley Joins the Outcomes4Me Executive Team to Accelerate Growth and Support Mission of Empowering Patients with Cancer

Outcomes4Me Inc., the leading direct-to-patient health technology company leveraging AI to revolutionize cancer care, announced today that Jim Longley, most recently the Senior Vice President: AI Partnerships at OpenEvidence, has joined Outcomes4Me as Chief Revenue Officer. With more than two decades of senior leadership experience across healthcare technology, commercial strategy, and business development, Jim will lead Outcomes4Me's revenue organization as the company enters its next exciting

Yahoo·06:00

Freedom Capital Markets downgrades Doximity to Hold from Buy

Fintel·20:27DOCS▲+0.5%

Intel upgraded, Reddit initiated: Wall Street's top analyst calls

Intel upgraded, Reddit initiated: Wall Street's top analyst calls

Yahoo·09:38

Freedom Capital Markets Downgrades Doximity to Hold, Raises Price Target to $27

Freedom Capital Markets analyst Gene Mannheimer downgrades Doximity (NYSE:DOCS) from Buy to Hold and raises the price target from $24 to $27.

Benzinga·06:16DOCS▲+0.5%

Doximity (NYSE:DOCS): A Quality Investment with Superior Returns on Capital

Doximity (DOCS) excels as a quality stock: 125% ROIC, no debt, strong cash conversion. See why its fundamentals appeal to long-term investors.

ChartMill·07:21DOCS▲+0.5%

3 Reasons to Avoid DOCS and 1 Stock to Buy Instead

Since March 2026, Doximity has been in a holding pattern, posting a small return of 2.8% while floating around $26.41. The stock also fell short of the S&P 500’s 12.1% gain during that period.

Yahoo·15:26DOCS▲+0.5%

Amplitude, GitLab, Doximity, Freshworks, and Sprinklr Shares Skyrocket, What You Need To Know

A number of stocks jumped in the afternoon session after quarterly earnings and upbeat corporate commentary signaled that artificial intelligence is driving growth across enterprise software rather than threatening legacy business models.

Yahoo·03:01DOCS▲+0.5%

Doximity (DOCS) Price Target Increased by 12.72% to 30.32

Fintel·02:30DOCS▲+0.5%

1 Software Stock on Our Buy List and 2 Facing Challenges

Software is eating the world, and virtually no business is left untouched by it. Companies bringing it to life have been rewarded with explosive earnings growth, and the upward trend shows no signs of stopping as the industry has posted a 44.6% gain over the past six months, beating the S&P 500 by 32.9 percentage points.

Yahoo·16:13

Overworked Doctors Bet on AI to Boost Their Pay

SAN FRANCISCO, August 25, 2026--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected source of optimism in AI. Rather than viewing the technology as a threat, nearly a quarter expect it to increase their total compensation within the next year, and two-thirds believe staying current with AI will give them a meaningful earnings edge over peers who don't.

Yahoo·10:05DOCS▲+0.5%

Reasons to Retain Doximity Stock in Your Portfolio for Now

DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.

Yahoo·15:47DOCS▲+0.5%

Barclays Maintains Equal-Weight on Doximity, Raises Price Target to $27

Barclays analyst Glen Santangelo maintains Doximity (NYSE:DOCS) with a Equal-Weight and raises the price target from $20 to $27.

Benzinga·07:06DOCS▲+0.5%

Doximity (DOCS) Stock Looks Cheap On Cash Flow Yet Fair On Earnings

Doximity stock has had a difficult five year stretch, with shareholders seeing the share price decline 71.8%, even as recent AI driven products have drawn fresh attention. At the current price near US$24.94, the key issue is whether the latest enthusiasm lines up with what the intrinsic value and market based checks say about Doximity. Over five years, the share price decline of 71.8% points to investors reassessing what they are willing to pay for Doximity. Growth expectations around...

Yahoo·14:10DOCS▲+0.5%

Doximity (DOCS) Could Be 26% Below Fair Value On Strong Earnings Guidance

Doximity (DOCS) is back in focus after its latest quarterly report showed higher sales, raised full year revenue guidance, and continued margin pressure tied to heavier spending on AI tools. See our latest analysis for Doximity. At a share price of US$24.94, Doximity has seen a 30 day share price return of 15.89% and a 90 day share price return of 25.58%. However, the year to date share price return is down 42.39% and the 1 year total shareholder return is down 60.79%. This points to...

Yahoo·20:14DOCS▲+0.5%

A Doximity Director Moved 7,500 Shares the Day the Stock Popped 33%. Here's What to Know

This sale was executed under a pre-established Rule 10b5-1 trading plan adopted in February.

Yahoo·08:53DOCS▲0.5%

What Investors Should Know of This Doximity Officer's Latest Insider Transaction

Sitaram's sale was driven by tax obligations from option exercises and RSU vesting, not a shift in conviction.

Yahoo·07:51DOCS▲+0.5%

Doximity Handed Its President 150,000 Options Last Month. Here's What the Latest Filing Signals for Investors

Restricted stock unit vesting triggered a routine sell-to-cover sale, reducing Zatz's direct holdings by 8% while leaving him with $1.3 million in remaining equity.

Yahoo·07:44DOCS▲+0.5%

Rapid7, 8x8, Doximity, Marqeta, and Tenable Shares Are Soaring, What You Need To Know

A number of stocks jumped in the afternoon session after the Bureau of Labor Statistics reported that the July Producer Price Index was completely flat month-over-month—coming in below expectations for a 0.2% increase—following the Consumer Price Index print (released earlier in the week) which showed a mild 0.1% monthly increase and an annual inflation rate cooling to 3.4%. Together, the data points suggest price pressures are moderating across both wholesale and consumer levels, taking the urg

Yahoo·03:21DOCS▲+0.5%

Doximity (DOCS) Q1 2027 Earnings Call Transcript

Revenue grew 7% as AI adoption accelerated, with AI Scribe users surging 10-fold in July.

Yahoo·20:03DOCS▲+0.5%

Doximity Doubled, Then Gave Most of It Back. Here’s Why the Market Doesn’t Trust the Rally

For a few hours on August 7, Doximity, Inc. (NYSE:DOCS) appeared to be the story of the earnings season. The medical-networking platform’s stock more than doubled overnight following its fiscal first-quarter report, with CEO Jeffrey Tangney mentioning a metric that piqued traders’ interest: the company’s new AI Search product, he claimed on the results call, […]

Yahoo·19:35DOCS▲+0.5%

Truist Securities Maintains Hold on Doximity, Raises Price Target to $24

Truist Securities analyst Jailendra Singh maintains Doximity (NYSE:DOCS) with a Hold and raises the price target from $19 to $24.

Benzinga·07:48DOCS▲+0.5%

1 Cash-Producing Stock with Promising Prospects and 2 We Ignore

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Yahoo·00:37

Atlassian and Doximity Just Surged 30% After Earnings: 3 Software Stocks with the Same Setup

GitLab, UiPath, and Asana have similar setups that could lead to big post-earnings jumps.

Yahoo·13:49DOCS▲+0.5%

Wells Fargo Downgrades Doximity (DOCS)

Fintel·06:36DOCS▲+0.5%